MedTrace Logo

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

NCT00988494 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2012-11-22

No results posted yet for this study

Summary

Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.

Conditions

  • Persistent Corneal Epithelial Defect

Interventions

DRUG

DE-105 ophthalmic solution

Topical ocular application

DRUG

DE-105 ophthalmic solution

Topical ocular application

DRUG

Placebo ophthalmic solution

Topical ocular application

Sponsors & Collaborators

  • Santen Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00988494 on ClinicalTrials.gov